Clinical Trial

A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The aim of this study is to evaluate the efficacy and safety of ESG401 in patients with unresectable locally advanced or metastatic HR+/HER2- breast cancer.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2024-04-24; most recent amendment 2025-06-17.
Status change: Not Yet Recruiting → Recruiting 2024-07-17
Trial Details
NCT Number NCT06383767
Lead Sponsor Qilu Pharmaceutical Co., Ltd.
Conditions Metastatic Breast Cancer
Enrollment 378 participants
Start Date 2024-07-11
Primary Completion 2027-06-30 (estimated)
Study Completion 2028-07-31 (estimated)
Updated on ClinicalTrials.gov 2025-06-19